BioMarin Pharmaceutical Inc (BMRN) - Financial and Strategic SWOT Analysis Review

  • ID: 1291947
  • SWOT Analysis
  • 62 pages
  • GlobalData
  • BioMarin Pharmaceutical Inc.
1 of 5

FEATURED COMPANIES

  • Amicus Therapeutics Inc
  • Biogen Inc
  • Enzon Pharmaceuticals Inc
  • Genzyme Corp
  • Shire Plc
  • Tesaro Inc
  • MORE
BioMarin Pharmaceutical Inc (BMRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

BioMarin Pharmaceutical Inc (BioMarin) is a biopharmaceutical company which develops and commercializes innovative pharmaceuticals for treatment of serious diseases and medical conditions such as Kyndrisa (drisapersen), Duchenne muscular dystrophy (DMD), phenylketonuria (PKU), achondroplasia, late infantile neuronal ceroid lipofuscinosis (CLN2) and hemophilia A. Its product portfolio consists of products and multiple clinical and preclinical product candidates. The company operates through its manufacturing facilities in Novato, California and has its presence in US, Europe, Latin America, the Middle East, and Asia-Pacific. BioMarin is headquartered in San Rafael, California, the US.

BioMarin Pharmaceutical Inc Key Recent Developments

Feb 22, 2018: BioMarin Reports Fourth Quarter 2017 Financial Results
Feb 05, 2018: BioMarin Announces 20 Presentations at 14th Annual WORLDSymposium 2018
Dec 14, 2017: Gene therapy success could lead to cure for haemophilia
Dec 09, 2017: New Therapies Improve Outlook for Bleeding and Clotting Disorders
Oct 26, 2017: BioMarin Announces Third Quarter 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amicus Therapeutics Inc
  • Biogen Inc
  • Enzon Pharmaceuticals Inc
  • Genzyme Corp
  • Shire Plc
  • Tesaro Inc
  • MORE
Section 1 - About the Company
  • BioMarin Pharmaceutical Inc - Key Facts
  • BioMarin Pharmaceutical Inc - Key Employees
  • BioMarin Pharmaceutical Inc - Key Employee Biographies
  • BioMarin Pharmaceutical Inc - Major Products and Services
  • BioMarin Pharmaceutical Inc - History
  • BioMarin Pharmaceutical Inc - Company Statement
  • BioMarin Pharmaceutical Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • BioMarin Pharmaceutical Inc - Business Description
  • Product Category: Aldurazyme (laronidase)
  • Overview
  • Performance
  • Product Category: Brineura (cerliponase alfa)
  • Overview
  • Performance
  • Product Category: Firdapse
  • Overview
  • Performance
  • Product Category: Kuvan (sapropterin hydrochloride)
  • Overview
  • Performance
  • Product Category: Naglazyme (galsulfase)
  • Overview
  • Performance
  • Product Category: Vimizim (elosulfase alfa)
  • Overview
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Latin America
  • Performance
  • Geographical Segment: Rest of the World
  • Performance
  • Geographical Segment: United States
  • Performance
  • BioMarin Pharmaceutical Inc - Corporate Strategy
  • BioMarin Pharmaceutical Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • BioMarin Pharmaceutical Inc - Strengths
  • BioMarin Pharmaceutical Inc - Weaknesses
  • BioMarin Pharmaceutical Inc - Opportunities
  • BioMarin Pharmaceutical Inc - Threats
  • BioMarin Pharmaceutical Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • BioMarin Pharmaceutical Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Feb 05, 2018: BioMarin Announces 20 Presentations at 14th Annual WORLDSymposium 2018
  • Dec 14, 2017: Gene therapy success could lead to cure for haemophilia
  • Dec 09, 2017: New Therapies Improve Outlook for Bleeding and Clotting Disorders
  • Oct 26, 2017: BioMarin Announces Third Quarter 2017 Financial Results
  • Oct 18, 2017: BioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York
  • Oct 11, 2017: BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York
  • Oct 03, 2017: BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors
  • Aug 02, 2017: BioMarin Announces Second Quarter 2017 Financial Results
  • May 04, 2017: BioMarin Announces First Quarter 2017 Financial Results
  • Feb 23, 2017: BioMarin Announces Fourth Quarter and Full Year 2016 Financial Results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • BioMarin Pharmaceutical Inc, Key Facts
  • BioMarin Pharmaceutical Inc, Key Employees
  • BioMarin Pharmaceutical Inc, Key Employee Biographies
  • BioMarin Pharmaceutical Inc, Major Products and Services
  • BioMarin Pharmaceutical Inc, History
  • BioMarin Pharmaceutical Inc, Subsidiaries
  • BioMarin Pharmaceutical Inc, Joint Venture
  • BioMarin Pharmaceutical Inc, Key Competitors
  • BioMarin Pharmaceutical Inc, Ratios based on current share price
  • BioMarin Pharmaceutical Inc, Annual Ratios
  • BioMarin Pharmaceutical Inc, Annual Ratios
  • BioMarin Pharmaceutical Inc, Interim Ratios
  • BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • BioMarin Pharmaceutical Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • BioMarin Pharmaceutical Inc, Performance Chart (2013 - 2017)
  • BioMarin Pharmaceutical Inc, Ratio Charts
  • BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Tesaro Inc
  • Shire Plc
  • Protalix BioTherapeutics Inc
  • Genzyme Corp
  • Enzon Pharmaceuticals Inc
  • BioSpecifics Technologies Corp
  • Biogen Inc
  • Amicus Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll